Dyadic International develops and licenses proprietary microbial protein production platforms, principally the C1 platform—a genetically engineered microorganism designed to produce proteins, enzymes, and biopharmaceutical products—along with other proprietary technologies such as Dapibus™. The company generates revenue through research and development collaborations, licensing agreements for its platforms to biopharmaceutical and pharmaceutical companies, and milestone payments and royalties from partners seeking to develop and commercialize products using its technologies. Dyadic operates in a highly competitive biotechnology market and relies heavily on third-party contract research organizations and service providers for development, manufacturing, and clinical activities, with its future success dependent on maintaining technological advantages in product quality, safety, productivity, and cost-effectiveness while navigating uncertain regulatory requirements for genetically modified organisms.